-
公开(公告)号：US08119358B2
公开(公告)日：2012-02-21
申请号：US12106070
申请日：2008-04-18
IPC分类号： G01N33/53
CPC分类号： G06F19/3431 , G01N33/48714 , G01N33/6893 , G01N2800/042 , G01N2800/52 , G06Q50/22 , G16H50/30 , Y02A90/22
摘要： The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
摘要翻译： 本发明描述了可用于预测个体将发展成为糖尿病的可能性的生物标志物。 生物标志物也可用于筛选大群体，以鉴定患有糖尿病发展风险的个体。
-
公开(公告)号：US08409816B2
公开(公告)日：2013-04-02
申请号：US13253578
申请日：2011-10-05
CPC分类号： G06F19/3431 , G01N33/48714 , G01N33/6893 , G01N2800/042 , G01N2800/52 , G06Q50/22 , G16H50/30 , Y02A90/22
摘要： The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
-
公开(公告)号：US07723050B2
公开(公告)日：2010-05-25
申请号：US12501385
申请日：2009-07-10
IPC分类号： G01N33/53
CPC分类号： G06F19/3431 , G01N33/48714 , G01N33/6893 , G01N2800/042 , G01N2800/52 , G06Q50/22 , G16H50/30 , Y02A90/22
摘要： The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
摘要翻译： 本发明描述了可用于预测个体将发展成为糖尿病的可能性的生物标志物。 生物标志物也可用于筛选大群体，以鉴定患有糖尿病发展风险的个体。
-
公开(公告)号：US20090271124A1
公开(公告)日：2009-10-29
申请号：US12501385
申请日：2009-07-10
IPC分类号： G06F19/00
CPC分类号： G06F19/3431 , G01N33/48714 , G01N33/6893 , G01N2800/042 , G01N2800/52 , G06Q50/22 , G16H50/30 , Y02A90/22
摘要： The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
摘要翻译： 本发明描述了可用于预测个体将发展成为糖尿病的可能性的生物标志物。 生物标志物也可用于筛选大群体，以鉴定患有糖尿病发展风险的个体。
-
公开(公告)号：US20090012716A1
公开(公告)日：2009-01-08
申请号：US12106070
申请日：2008-04-18
CPC分类号： G06F19/3431 , G01N33/48714 , G01N33/6893 , G01N2800/042 , G01N2800/52 , G06Q50/22 , G16H50/30 , Y02A90/22
摘要： The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
摘要翻译： 本发明描述了可用于预测个体将发展成为糖尿病的可能性的生物标志物。 生物标志物也可用于筛选大群体，以鉴定患有糖尿病发展风险的个体。
-
6.发明申请Systems and Methods for Developing Diagnostic Tests Based on Biomarker Information from Legacy Clinical Sample Sets 审中-公开基于传统临床样本集的生物标志物信息开发诊断测试的系统和方法公开(公告)号：US20130267442A1
公开(公告)日：2013-10-10
申请号：US13746216
申请日：2013-01-21
IPC分类号： G01N33/53
CPC分类号： G01N33/6842 , C12Q1/6883 , G01N33/5302 , G01N2570/00 , G01N2800/56 , G01N2800/60 , G16B20/00
摘要： Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 μL or less of a legacy clinical sample.
摘要翻译： 公开的是基于来自传统临床样品组的生物标志物信息开发诊断测试（例如检测，筛选，监测和预后测试）的系统和方法，其仅具有小样本体积（例如，约0.05至约1.0mL或更少 样品）通常可用。 例如，可以通过使用单分子检测在临床样品中检测生物标志物（例如，约10,50,100,150,200,300或更多），并且可以在包括约1的测定中检测每个生物标志物 muL或更少的遗留临床样品。
-
7.发明申请SYSTEMS AND METHODS FOR DEVELOPING DIAGNOSTIC TESTS BASED ON BIOMARKER INFORMATION FROM LEGACY CLINICAL SAMPLE SETS 有权基于生物标志物信息的诊断试剂盒的诊断检测系统和方法公开(公告)号：US20120289434A1
公开(公告)日：2012-11-15
申请号：US13561913
申请日：2012-07-30
IPC分类号： C40B60/12
CPC分类号： G01N33/6842 , C12Q1/6883 , G01N33/5302 , G01N2570/00 , G01N2800/56 , G01N2800/60 , G06F19/18
摘要： Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 μL or less of a legacy clinical sample.
摘要翻译： 公开的是基于来自传统临床样品组的生物标志物信息开发诊断测试（例如检测，筛选，监测和预后测试）的系统和方法，其仅具有小样本体积（例如，约0.05至约1.0mL或更少 样品）通常可用。 例如，可以通过使用单分子检测在临床样品中检测生物标志物（例如，约10,50,100,150,200,300或更多），并且可以在包括约1的测定中检测每个生物标志物 μL或更少的遗留临床样本。
-
公开(公告)号：US08097425B2
公开(公告)日：2012-01-17
申请号：US11717280
申请日：2007-03-12
CPC分类号： G01N33/6842
摘要： The invention provides methods, compositions, and kits for multiplex fractionation of proteins in a sample. Protein-binding molecules, such as small epitope antibodies or small epitope aptamers, are used for multiplex fractionation of proteins in a protein containing sample. Detection of fractionated proteins may be used for characterization of proteins in a sample in applications such as expression profiling, identification and/or quantification of proteins in a sample, and identification or detection of biomarkers.
摘要翻译： 本发明提供了用于样品中蛋白质多重分级分离的方法，组合物和试剂盒。 蛋白质结合分子，如小表位抗体或小表位适配子，用于蛋白质含量样品中多重分级分离。 分析蛋白质的检测可以用于表征样品中的蛋白质，例如样品中的蛋白质的表达谱，鉴定和/或定量，以及生物标志物的鉴定或检测。
-
9.发明授权Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets 有权基于遗传临床样本集的生物标志物信息开发诊断测试的系统和方法公开(公告)号：US08357497B2
公开(公告)日：2013-01-22
申请号：US13561913
申请日：2012-07-30
CPC分类号： G01N33/6842 , C12Q1/6883 , G01N33/5302 , G01N2570/00 , G01N2800/56 , G01N2800/60 , G06F19/18
摘要： Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 μL or less of a legacy clinical sample.
摘要翻译： 公开的是基于来自传统临床样品组的生物标志物信息开发诊断测试（例如检测，筛选，监测和预后测试）的系统和方法，其仅具有小样本体积（例如，约0.05至约1.0mL或更少 样品）通常可用。 例如，可以通过使用单分子检测在临床样品中检测生物标志物（例如，约10,50,100,150,200,300或更多），并且可以在包括约1的测定中检测每个生物标志物 μL或更少的遗留临床样本。
-
10.发明授权Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets 有权基于遗传临床样本集的生物标志物信息开发诊断测试的系统和方法公开(公告)号：US08232065B2
公开(公告)日：2012-07-31
申请号：US12300019
申请日：2007-05-08
CPC分类号： G01N33/6842 , C12Q1/6883 , G01N33/5302 , G01N2570/00 , G01N2800/56 , G01N2800/60 , G06F19/18
摘要： Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 μL or less of a legacy clinical sample.
摘要翻译： 公开的是基于来自传统临床样品组的生物标志物信息开发诊断测试（例如检测，筛选，监测和预后测试）的系统和方法，其仅具有小样本体积（例如，约0.05至约1.0mL或更少 样品）通常可用。 例如，可以通过使用单分子检测在临床样品中检测生物标志物（例如，约10,50,100,150,200,300或更多），并且可以在包括约1的测定中检测每个生物标志物 μL或更少的遗留临床样本。
-
-
-
-
-
-
-
-
-
搜索结果
68 条记录 (耗时 0.03 秒)
